PleXus Communications
C

Emerging Cellular and Targeted Therapy Options for the Management of Large B-Cell Lymphomas

By PleXus Communications FEATURING Caron Jacobson
By PleXus Communications FEATURING Caron Jacobson
156 views
February 15, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
13:07
Moffitt Cancer Center

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Feat. J. Chavez
53:42
PleXus Communications

Managing Women's Health in Menopause: Evolving Approaches for t…

Feat. J. Simon, T. Iyer, A. Fiffick, M. Minkin
09:18
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…

Feat. J. Westin
10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

Feat. R. Gale
08:23
Total Health

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Feat. J. Chandler, B. Randolph, M. Onciu
22:09
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

New Updates in Frontline DLCBL

Feat. L. Nastoupil
08:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outpatient Management of CAR-T and Bi-Speci…

Feat. R. Bansal
04:08
GRACE

CAR T-Cell Therapy Side Effects for Blood Cancers

Feat. A. Goodman
62:02
UChicago Medicine

New Treatment Strategies in DLBCL

Feat. L. Sehn
09:45
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Therapeutic Options for Pts With Primary …

Feat. M. Kamdar
16:03
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New Algorithm for 2L LBCL

Feat. J. Westin
15:26
Moffitt Cancer Center

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Feat. A. Lazaryan
32:52
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

The Improbable History of CAR T-Cells

Feat. C. June
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

15:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Has R-CHOP Really Been Replaced as Initial Therapy of DLB…

Feat. J. Friedberg
10:27
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Rates of CRS and ICANS From CIBMTR Data o…

Feat. J. DiPersio
25:44
Tara Graff

DLBCL Updates From iCML 2023

07:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Putting the CAR-T Before the Horse - Impr…

Feat. L. Shune